<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840915</url>
  </required_header>
  <id_info>
    <org_study_id>MS200647_0024</org_study_id>
    <secondary_id>2018-004040-28</secondary_id>
    <nct_id>NCT03840915</nct_id>
  </id_info>
  <brief_title>M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate the safety and tolerability of M7824 in
      combination with chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Anticipated">October 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Day 1 to Day 21 (Cycle 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs) and Treatment Related Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of M7824 Observed Immediately at the End of Infusion (Ceoi)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of M7824 Observed Immediately Before Next Dosing (Ctrough)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of M7824</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of M7824</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of M7824</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Serum Concentration (Tmax) of M7824</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of M7824</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of M7824, as Assessed by Anti-drug Anti-body (ADA) Assay</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: Docetaxel + M7824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824</arm_group_label>
    <arm_group_label>Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed will be administered intravenously at a dose of 500 mg/ m^2 over 10 minutes every 21 days.</description>
    <arm_group_label>Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be administered intravenously at a dose of 1250 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel will be administered intravenously at a dose of 75 mg/m^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort D: Docetaxel + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M7824</intervention_name>
    <description>M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.</description>
    <arm_group_label>Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M7824</intervention_name>
    <description>M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.</description>
    <arm_group_label>Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824</arm_group_label>
    <arm_group_label>Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824</arm_group_label>
    <arm_group_label>Cohort D: Docetaxel + M7824</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered intravenously at a dose of 200 mg/m2 over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).</description>
    <arm_group_label>Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants greater than or equals to (&gt;=) 18 years of age inclusive at the time of
             signing the informed consent

          -  Participants who have histologically confirmed diagnosis of Stage IV NSCLC:

               1. Participants in Cohort A, B, and C must not have received prior systemic therapy
                  treatment for their Stage IV NSCLC

               2. Participants who had disease progression on previous treatment with Programmed
                  death-ligand 1 (PD- L1) inhibitors in combination with platinum-based
                  chemotherapy are enrolled in Cohort D, as long as therapy was completed at least
                  28 days of the first study intervention.

          -  Have measurable disease based on Response evaluation criteria in solid tumors (RECIST)
             1.1

          -  Have a life expectancy of at least 3 months

          -  Availability of archived tumor material (less than [&lt;] 6 months old) adequate for
             biomarker analysis is mandatory at Screening, central laboratory confirmation is
             required. Fresh biopsies should be collected if archived tumor material is not
             available

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at study
             entry and date of first dose

        Exclusion Criteria:

          -  The participant's tumor harbors an epidermal growth factor receptor (EGFR) sensitizing
             (activating) mutation,ROS1 rearrangement, or BRAF V600E mutation or anaplastic
             lymphoma kinase (ALK) positive, if targeted therapy is locally approved

          -  Mixed small cell with NSCLC cancer histology

          -  Has received major surgery within 4 weeks prior to the first dose of study
             intervention; received thoracic radiation therapy (RT) of &gt; 30 gray (Gy) within 6
             months prior to the first dose of study intervention

          -  Previous malignant disease (other than the target malignancy to be investigated in
             this study) within the last 3 years

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Participants with previously treated brain metastases may participate
             provided they are clinically stable for at least 2 weeks after the end of the RT and,
             have no evidence of new or enlarging brain metastases evaluated by imaging, preferably
             brain magnetic resonance imaging (MRI)

          -  Known severe hypersensitivity to study intervention or any components in their
             formulations

          -  For participants in Cohort A, B and C: Has received prior systemic therapy for Stage
             IV NSCLC, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic
             T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other
             antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)

          -  Unable to tolerate computed tomography (CT) or MRI in the opinion of the Investigator
             and/or allergy to contrast material.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F McClay</last_name>
      <email>emcclay@ccare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward F McClay</last_name>
      <email>emcclay@ccare.com</email>
    </contact>
    <investigator>
      <last_name>Edward F McClay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology - Oncology Associates of Treasure Coast - Hematology-Oncology Associates of Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael S Wertheim</last_name>
      <email>mwertheim@hemoncfl.com</email>
    </contact>
    <investigator>
      <last_name>Michael S Wertheim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington Oncology Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Firas Badin</last_name>
      <email>firas.badin@bhsi.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland - DUPLICATE/Pediatric Surgery</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Rolfo</last_name>
      <email>christian.rolfo@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RCCA MD LLC - Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph V Boccia</last_name>
      <email>nbongiorno@regionalcancercare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RCCA MD LLC - Bethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph V Boccia</last_name>
      <email>rboccia@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Ralph V Boccia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor I Rybkin</last_name>
      <email>irybkin1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leora Horn</last_name>
      <email>leora.horn@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel - Geriatrie</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lore Decoster</last_name>
      <email>lore.decoster@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Prenen</last_name>
      <email>hans.prenen@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent - Medical Oncology</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veerle Surmont</last_name>
      <email>veerle.surmont@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Paulus</last_name>
      <email>apaulus@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Maarten</name>
      <address>
        <city>Mechelen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Lambrechts</last_name>
      <email>marc.lambrechts@emmaus.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice cedex 02</city>
        <state>Alpes Maritimes</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josiane Otto</last_name>
      <email>josiane.otto@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone# - CPCEM CIC - Bat F 1er étage</name>
      <address>
        <city>Marseille cedex 5</city>
        <state>Bouches-du-Rhône</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greillier Laurent</last_name>
      <email>laurent.greillier@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc - Unité de Phase I</name>
      <address>
        <city>Dijon cedex</city>
        <state>Côte-d'Or</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Ghiringhelli</last_name>
      <email>fghiringhelli@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Maison du Ha</name>
      <address>
        <city>Bordeaux cedex</city>
        <state>Gironde</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remi Veillon</last_name>
      <email>remi.veillon@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO - Site René Gauducheau</name>
      <address>
        <city>Nantes Cedex 01</city>
        <state>Loire Atlantique</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Hiret</last_name>
      <email>sandrine.hiret@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris - Service d'Oncologie Médicale</name>
      <address>
        <city>Paris Cedex 05</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale</name>
      <address>
        <city>Poitiers Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isambert Nicolas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.intrapidclinicaltrials.com/en</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0024</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Bintrafusp alfa (proposed INN)</keyword>
  <keyword>M7824</keyword>
  <keyword>Stage IV</keyword>
  <keyword>INTR@PID LUNG 024</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

